Jean Christopher Chamcheu

Assistant Professor

School Basic Pharm & Toxicol Sci

PHAR

318-342-6820

Jean Christopher Chamcheu, PhD
Assistant Professor, Pharmacy

Education

Ph D

2010, Dermatology & Venereology
Faculty of Medicine, Uppsala University, Sweden

MS

2004, Biomedicine
Faculty of Health Sciences, Linköping University

BS

2000, Biochemistry
Faculty of Science, Dschang University, Cameroon

Biographical Sketch

For over ten years, Dr. Chamcheu has devoted his research efforts to identifying and understanding the genetic and molecular basis of human skin diseases and to develop novel mechanism-based small molecular weight natural dietary and synthetic scaffold agents for the prevention and treatments of hereditary, stress-induced, and chronic inflammatory skin diseases and skin cancers. As a graduate and postdoctoral trainee, he identified disease molecular targets as markers for genodermatoses [Epidermolysis bullosa simplex (EBS), Epidermolytic Icthyoses (EI)] and skin inflammation (psoriasis) and established 3D reconstituted human skin equivalent (RHSE) models that more closely mimic human skin. He employed these to investigate the biology and disease etiology and demonstrated for the first time the therapeutic effects of small molecule chemical chaperones and dietary compounds to treat EBS, EI, melanoma, and psoriasis.

As a tenure-track assistant professor at the ULM College of Pharmacy, he has been establishing an independent research program currently devoting a large portion of focused efforts to delineating the molecular diagnostic and disease mechanisms, and to establishing novel predictive biomarkers as targets of cutaneous hyperplasia and inflammation-related skin pathologies, particularly in psoriasis. His research program is also focused on developing natural and synthetic small molecules as target-specific responses for chemoprevention and chemotherapy of skin inflammation and cancers. His long-term goal is to identify biomarkers and novel therapeutic targets for halting and resolving inflammation and skin carcinogenesis. We are currently investigating the role of the central mTOR/Rac1 hub in psoriasis, and the role of intervention with natural products such as fisetin and their synthetic derivatives in epidermal differentiation, proliferation, and inflammation, as candidates or lead drugs for treating psoriasis and possibly other inflammatory conditions.

If successful our strategies could define the role of specific signaling pathway component(s), and preclinically develop natural and synthetic compounds individually or in combination or as adjuvants to FDA-approved drugs for long-term benefits of patients with psoriasis, and other hyperproliferative and chronic autoimmune disorders.

We have a solid publication record with over 36 PubMed indexed peer-reviewed research articles and reviews with over half of which Dr. Chamcheu appears as the first or corresponding author, 2 book chapters, 1 edited book, and over 38 published conference proceedings.

Positions and Employment

2000 - 2002 Research Technician, Institute of Medical Research & Studies of Medicinal Plants, Cameroon

2004 - 2004 Research Assistant, Dept. Of Biomedicine & Surgery, Linköping University, Sweden

2005 - 2010 Graduate Teaching Assistant, Dept. of Medical Sciences, Uppsala University, Sweden

2006 - 2006 Visiting Scientist, Centre for Cutaneous Research, Queen Mary University of London, UK

2005 - 2010 Graduate Research Assistant, Dermatology/Venereology, Uppsala University, Sweden

2010 - 2014 PostDoc. Research Associate, Dept. of Dermatology, University of Wisconsin, Madison, WI

2014 - 2017 Assistant Scientist, Dept. of Dermatology, University of Wisconsin, Madison, WI

2014 - 2017 Instructor, Dept. of Dermatology, University of Wisconsin, Madison, WI

2017 - present Assistant Professor, School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana-Monroe, Monroe, LA

Other experience and Professional Society Memberships (Current)

2006-Member, The Swedish Society for Biochemistry and Molecular Biology (SSBMB)

2008-Member, The European Society for Dermatological Research (EDSR)

2008-Member, Society for Investigative Dermatology (SID)

2009-2019-Member, American The American Chemical Society (ACS)

2019 -Member, The American Society of Pharmacognosy (ASP)

Editorial Appointment and Reviewer for Scientific Journals (Current Selected few)

British Journal of Dermatology, British Journal of Pharmacology, Journal of Investigative Dermatology, Experimental Dermatology, Scientific Reports, Cancer Research, Nutrients, Chemical Research in Toxicology, Drug design, Development & Therapy, Biologics: Targets and Therapy, Psoriasis: Targets and Therapy, Life Sciences, PLoS One, Photochemistry and Photobiology, Molecular Medicine, Enliven: Clinical Dermatology, International Journal of Nanomedicine, International Journal of Molecular Sciences.

Honors and Awards

2004 Recipient, Skin Biology & Keratin Disease Research Scholarship, Uppsala University, Sweden

2005 Recipient, Pre-doc trainee grants from Royal Astella & Medical Research Council Sweden

2006 Recipient, Pre-doctoral Travel Awards, Welander & Stiftelson Foundation, Uppsala University, Sweden

2011 Recipient, Pachyonychia Congenita Travel Award for 71st SID meeting, (May 4-7) Phoenix, AR, USA

2012 Recipient, The 72nd SID Annual Meeting PhD-Retreat, (May 9-12) Raleigh, NC, USA

2016 Recipient, American Skin Association Carson Research Scholar Award in Psoriasis, USA.

2016 Recipient, Fellow Travel Award from the Society for Investigative Dermatology, USA, to present my research work in SID annual meeting, Scottsdale, AR, (May 11-14)

2016 Recipient, Junior Scientists Travel Award from International Journal of Molecular Sciences, to SID meeting, May 11-14, Scottsdale, AR, USA

2018 Recipient, Pilot Award from Louisiana Biomedical Research Network (LBRN) for ULM COP, USA

2018 Recipient, Faculty Research Support (FRS) Grant from ULM College of Pharmacy, USA

2018 PI/Mentor, Summer Graduate Research Award for a graduate student.

Contributions to Science:

My contribution to skin and cancer biology and disease and therapeutics are discussed below.

Discovery of the molecular basis of inflammatory skin diseases, and establishment of in vitro engineered three-dimensional (3D) normal and diseased human skin models of psoriasis and skin cancers, and for testing new therapies: Earlier, we defined the molecular basis of hereditary and inflammatory skin diseases, established and characterized the pharmacological effects and the role of natural small molecules using 2D culture and 3D bioengineering skin models. These RHSE systems were used to investigate the biology, etiology, and treatment of dermatoses and I have successfully developed a similar system to modulate human psoriasis, melanoma, and UV-induced skin cancer and employ all with application on testing treatments.

Developing natural products-based therapies for cutaneous hyperproliferation, inflammation, and cancers: There is a considerable emphasis to identify potential chemotherapeutic agents from food consumed by humans. The development of effective therapeutics for humans requires conclusive evidence of their efficacy in 3D models that faithfully recapitulate disease prior to preclinical models closely emulating human disease. We utilized 2D and 3D, and preclinical in vivo animal models to develop therapeutic agents for non-melanoma/UV-induced skin and prostate cancers, and inflammatory disorders therapeutics. We explored the usefulness of several natural dietary agents, delphinidin, green tea (EGCG), VitD3; fisetin etc., as anti-psoriatic agents, and a huge portion of our focus was devoted to defining several molecular disease targets. We also investigated the potential usefulness of these small molecule inhibitor agents and established a novel predictive mechanism-based therapy approach for drug development. In fact, we proved that these dietary agents promoted skin regeneration and attenuated psoriasis-like parameters acting as promising anti-psoriatic or anticancer agents.

Nanomedicine and nanotechnology delivery of natural products for the treatment of skin inflammation and cancers: There is considerable emphasis on developing potential chemotherapeutic dietary product agents present in food consumed by humans while enhancing their poor bioavailability as well as transdermal delivery. The development requires conclusive evidence of agent efficacy in preclinical models that faithfully recapitulate human disease. I have demonstrated a record of accomplished and productive research in the area of nanotechnology and the successful delivery of agents for the treatment of skin and prostate cancer as well as inflammation in psoriasis.

List of selected publications:

Roy T, Boateng ST, Banang-Mbeumi S, Singh PK, Basnet P, Chamcheu RN, Ladu F, Chauvin I, Spiegelman SS, Hill RA, Kousoulas KG, Nagalo MB, Walker AL, Fotie J, Murru S, Sechi M, Chamcheu JC*. (2021). Synthesis, Inverse Docking-Assisted Identification and in vitro Biological Characterization of Flavonol-based Analogs of Fisetin as c-Kit, CDK2 and mTOR Inhibitors against Melanoma and Non-melanoma Skin Cancers. Bioorg Chem. 2020 Dec 30;107:104595. PMID: 33450548.
Chamcheu JC*, Esnault S, Adhami VM, Noll AL, Banang-Mbeumi S, Roy T, Singh SS, Huang S, Kousoulas KG, Mukhtar H. (2019) Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models. Cells. 2019 Sep 15;8(9). PMID: 31540162.
Chamcheu JC*, Roy T, Uddin MB, Banang-Mbeumi S, Chamcheu RN, Walker AL, Liu YY, Huang S. (2019). Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy. Cells. 2019
Jul 31;8(8):803. PMID: 31370278.
Chamcheu JC*, Siddiqui IA, Adhami VM, Esnault S, Bharali DJ, Babatunde AS, Adame S, Massey RJ, Wood GS, Longley BJ, Mousa SA, Mukhtar H. (2018) (Chitosan-based nanoformulated (-)-epigallocatechin-3- gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. Int J Nanomedicine. 2018 Jul 20;13:4189-4206. PMCID: PMC6059258.
Karrys A, Rady I, Chamcheu RN, Sabir MS, Mallick S, Chamcheu JC*, Jurutka PW, Haussler MR, Whitfield GK. Bioactive Dietary VDR Ligands Regulate Genes Encoding Biomarkers of Skin Repair That Are Associated with Risk for Psoriasis (2018). Nutrients. 2018 Feb 4;10(2). pii: E174. doi: 10.3390/nu10020174. PMID: 29401702; PMCID: PMC5852750.
Rady I, Bloch MB, Chamcheu RN, Banang Mbeumi S, Anwar MR, Mohamed H, Babatunde AS, Jules-Roger Kuiate J, Noubissi FK., El Sayed KA, Whitfield GK, Chamcheu JC* (2018). Anticancer Properties of Graviola (Annona muricata): A Comprehensive Mechanistic Review. Oxid Med Cell Longev. 2018 Jul 30;2018:1826170. PMID: 30151067.
Chamcheu JC*, Rady I, Chamcheu RN, Siddique AB, Bloch MB, Banang Mbeumi S, Babatunde AS, Uddin MB, Noubissi FK, Jurutka PW, Liu YY, Spiegelman VS, Whitfield GK, El Sayed KA (2018). Graviola (Annona muricata) Exerts Anti-Proliferative, Anti-Clonogenic and Pro-Apoptotic Effects in Human Non-Melanoma Skin Cancer UW-BCC1 and A431 Cells In Vitro: Involvement of Hedgehog Signaling. Int J Mol Sci. 2018 Jun 16;19(6) :1791. PMID: 29914183; PMCID: PMC6032424.
Sanna V, Singh CK, Jashari R, Adhami VM, Chamcheu JC, Rady I, Sechi M, Mukhtar H, Siddiqui IA (2017). Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy. Sci Rep. 2017 Feb 1;7:41573. doi: 10.1038/srep41573. PubMed PMID: 28145499; PubMed Central PMCID: PMC5286400.
Chamcheu JC, Chaves-Rodriquez MI, Vaqar AM, Imtiaz AS, Wood GS, Longley BJ and Mukhtar H (2016). Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in human psoriasis and imiquimod-induced murine psoriasiform dermatitis model. Acta Derm Venereol. 2016 Aug 23;96(6):854-6. PMID: 26833029 PMCID: PMC5540143.
Chamcheu JC*, Adhami VM, Esnault S, Sechi M, Siddiqui IA, Satyshur KA, Syed DN, Chaves- Rodriquez MI, Longley BJ, Wood GS, Mukhtar H (2017). Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice. Antioxid Redox Signal. 2017 Jan 10;26(2):49-69. PMID: 27393705.
Chamcheu JC*, Pal HC, Siddiqui IA, Adhami VM, Ayehunie S, Boylan BT, Noubissi FK, Khan N, Syed DN, Elmets CA, Wood GS, Afaq F, Mukhtar H (2015). Prodifferentiation, anti-inflammatory and antiproliferative effects of delphinidin, a dietary anthocyanidin, in a full-thickness three-dimensional reconstituted human skin model of psoriasis. Skin Pharmacol Physiol. 2015;28(4):177-88.
Sanna V, Chamcheu JC, Pala N, Mukhtar H, Sechi M, Siddiqui IA(2015). Nanoencapsulation of natural triterpenoid celastrol for prostate cancer treatment. Int J Nanomedicine. 2015 Oct 30;10:6835-46. PMCID: PMC4636169.
Pal HC, Chamcheu JC, Athar M, Wood GS, Elmets CA, Mukhtar H and Afaq F (2015). Topical application of delphinidin reduces psoriasiform lesions in the flaky skin mouse model by inducing epidermal differentiation and inhibiting inflammation. British J Dermatol. 2015 Feb;172(2):354-64. PMCID: PMC4324120.
Syed DN, Chamcheu JC, Khan MI, Sechi M, Lall RK, Adhami VM, Mukhtar H( 2014). Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling. Biochem Pharmacol. 2014 Jun 1;89(3):349-60. PMID: 24675012 . PMCID: PMC4116133.
Calvo-Castro L, Syed DN, Chamcheu JC, Vilela FM, Pérez AM, Vaillant F, Rojas M, Mukhtar H (2013). Protective effect of tropical highland blackberry juice (Rubus adenotrichos Schltdl.) against UVB-mediated damage in human epidermal keratinocytes and in a reconstituted skin equivalent model. Photochem Photobiol. 2013, 89:1199-207. PMID: 23711186; PMCID: PMC3962679.

Licensure & Certification

Basic Life Support, American Heart Association (AHA). (November 30 2022 - Present)

Life Insurance Provider, LA DEPARTMENT OF INSURANCE. (May 30 2022 - May 2024)

Research Interests

The primary goals of our Molecular Dermatology and Experimental Therapeutics (MODET) Laboratory research are to;

Identify and understand the genetic and molecular basis of human skin disorders including skin carcinogenesis, inflammation, and genodermatoses as well as new insights into skin biology.
Identify, test, develop and deliver novel mechanism-based natural products and their synthetic scaffold entities for chemoprevention and chemotherapy of these skin diseases.

Few specific projects include:

Novel biomarkers discovery and mechanistic studies for chronic inflammatory skin diseases (psoriasis, atopic dermatitis), melanoma, and non-melanoma [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] skin cancers.
Investigating some of the natural dietary small molecules or "nutraceuticals" currently under intense investigation including cannabinoids, celastrol, curcumin, delphinidin, docosahexaenoic acid (DHA), fisetin, resveratrol, vitamin D, as well as natural products such as Graviola (Annona muricata) and Garcinia Kola.
Drug delivery using diverse formulations, nanotechnology, and nanomedicine delivery approach for identified promising target-directed therapeutics for use in chemoprevention and chemotherapy.

Our research program employs interdisciplinary research approaches that make use of regenerative medicine, molecular genetics, biochemical pharmacology, medicinal chemistry, structural molecular biology, and other cutting-edge molecular medicine technologies in conjunction with human skin bioengineering and preclinical murine models to elucidate fundamental questions in skin biology, dermatological sciences, delineate the molecular basis of skin diseases, and to develop novel treatments. Specific areas of focus include skin inflammation (psoriasis, dermatitis), cancer biology (melanoma and non-melanoma skin cancers), and keratin genodermatoses. We are also actively involved in chemoprevention and therapeutics, with emphasis on translational research that explores the utility of natural product-derived extract leads, their bioactive phytochemicals, and their synthetic scaffolds while also establishing the molecular basis of dermatological diseases to seek solutions to health conditions and preventions that will improve these disease patients’ quality of life. Our published and current work establishes novel predictive biomarkers and develops novel two-dimensional (2D) and 3D-tissue bio-engineered cultures using patients and healthy donors-derived skin cells, to model normal and diverse human skin diseases including; psoriasis, dermatitis, melanoma, BCC, SCC, EBS, and EI.

Through collaboration with natural products scientists, medicinal and synthetic chemists, pharmaceutics, pharmacologists, clinicians, and pharmaceutical industry research partners, our research also employs and generates pre-clinical in-vivo murine disease models, as well as discovery and development of potent anti-cancer, anti-inflammatory, and anti-proliferative compounds and extracts abundantly found in plants, pigmented fruits, and vegetables. The preclinical therapeutic proof-of-concept of promising bioactive dietary phytochemicals is validated for potential future interventions. We also work on the development of synthetic derivatives with enhanced bioavailability, efficacy, and stability. These collaborative programs seek to modulate and adopt cutting-edge technologies viz translational research geared towards delineating novel disease biomarkers, optimize and develop natural products and their derivatives for the management of skin diseases.

To date, some of the biomarkers discovery studies have elucidated the role of the central mTOR/Rho small GTPases, and other molecular targets in skin inflammatory conditions including skin cancers.

Recent Publications

Chamcheu, J. C., Syed, D., Whitfield, G. (2018). Nutraceuticals and the Skin: Roles in Health and Disease. Basel/MDPI: Nutrients/ MDPI.

Chamcheu, J. C., Walker, A., Noubissi, F. (2022). Natural and Synthetic Bioactives for Skin Health, Disease and Management (pp. https://www.mdpi.com/books/book/6515). Basel/MDPI: Nutrients/ MDPI.

Boateng, S. T., Roy, T., Torrey, K., Owunna, U., Banang-Mbeumi, S., Basnet, D., Niedda, E., Alexander, A., El Hage, D., Nagalo, B., Aryal, D., Findley, A., Seeram, N., Efimova, T., Sechi, M., Hill, R., Ma, H., Chamcheu, J., Murru, S. Synthesis, In-Silico and In-Vitro Biological Evaluation of Substituted Pyrazole Derivatives as Potential Anti-Tyrosinase, Anti-Skin Cancer, and Antioxidant Agents. ELSERVIER: JOURNAL OF ENZTME INHIBITION AND MEDICINAL CHEMISTRY.

Li, H., DaSilva, N., Liu, W., Xu, J., Dombi, G., Dain, J., Li, D., Chamcheu, J., Seeram, N., Ma, H. (2020). Thymocid®, a Standardized Black Cumin ( Nigella sativa) Seed Extract, Modulates Collagen Cross-Linking, Collagenase and Elastase Activities, and Melanogenesis in Murine B16F10 Melanoma Cells. Basel: Nutrients/MDPI.

Roy, K., Uddin, M., Roy, S., Hill, R., Marshall, J., Li, Y., Chamcheu, J., Lu, H., Liu, Y. (2020). Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylation. (pp. 653–667.). FASEB Bioadv/FASEB.

Wongjarupong, N., Yonli, A., Nagalo, B., Djigma, F., Somda, S., Hassan, M., Mohamed, E., Sorgho, A., Soubeiga, S., Compaore, T., Kiendrebeogo, I., Sanou, M., Diarra, B., Yang, H., Chen, C., Ouattara, A., Zohoncon, T., Martinson, J., Buetow, K., Chamcheu, J., Antwi, S., Borad, M., Simpore, J., Roberts, L. (2020). Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. Hepatol Commun./Wileys.

Aryal, D., Roy, T., Chamcheu, J., Jackson, K. (2020). Chronic Metabolic Acidosis Elicits Hypertension via Upregulation of Intrarenal Angiotensin II and Induction of Oxidative Stress. Basel and MDPI: Antioxidants.

Wongjarupong, N., Oli, S., Sanou, M., Djigma, F., Kiba Koumare, A., onli, A., Hassan, M., Mara, K., Harmsen, W., Therneau, T., Barro, O., Vodounhessi, G., Sawadogo, S., Chamcheu, J., Simpore, J., Roberts, L., Nagalo, B. (2021). Distribution and Incidence of Blood-Borne Infection among Blood Donors from Regional Transfusion Centers in Burkina Faso: A Comprehensive Study. (pp. 1577-1581). Am J Trop Med Hyg..

Chamcheu, J. C., WALKER, A., Noubissi-Kamdem, F. (2021). Natural and Synthetic Bioactives for Skin Health, Disease and Management. bASEL: Nutrients/ MDPI.

Nagalo, B., Zhou, Y., Loeuillard, E., Dumbauld, C., Barro, O., Elliott, N., Baker, A., Arora, M., Bogenberger, J., Meurice, N., Aslam, F., Raupach, E., Gabere, M., Basnakian, A., Simoes, C., Cannon, M., Post, S., Buetow, K., Chamcheu, J. C., Barrett, M., Duda, D., Jacobs, B., Borad, M. (2022). Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Monroe: Hepatology / Wileys.

Zhang, Y., Gabere, M., Taylor, M., Simoes, C., Barro, O., Tesfay, M., Graham, A., Ferdous, K., Savenka, A., Chamcheu, J. C., Washam, C., Alkam, D., Gies, A., Byrum, S., Conti, M., Kelly, T., Borad, M., Basnakian, A., Nagalo, B. (2022). Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Loussane: Front Oncology.

Li, H., Roy, T., Boateng, S. T., He, H., liu, C., liu, C., Wu, P., Seeram, N. P., Chamcheu, J. C., Ma, H. (2022). Standardized Pomegranate (Pomella®) and Red Maple (Maplifa®) Extracts and Their Phenolics Protect Type I Collagen by the Inhibition of Matrix Metalloproteinases, Collagenase, and Collagen Cross-Linking. Basel: Molecules/MDPI.

Attah, F. A., Lawal, B., Yusuf, A., Adedeji, O., Folahan, J., Akhigbe, K., Roy, T., Lawal, A., Ogah, N., Olorundare, O., Chamcheu, J. C. (2022). Nutritional and Pharmaceutical Applications of Under-Explored Knottin Peptide-Rich Phytomedicines. Basel: Plants / MDPI.

Roy, T., Banang-Mbeumi, S. C., Boateng, s. b., Ruiz, E., Chamcheu, R., Lin Kang, ., King, J., Walker, A. L., Nagalo, B. M., Kousoulas, K., HUANG, S., Chamcheu, J. C. (2023). Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation. Lausanne: Frontiers in Immunology.

Karrys, A., Rady, I., Chamcheu, R. N., Sabir, M., Mallick, S., Chamcheu, J. C., Jurutka, P., Haussler, M., Whitfield, G. K. (2018). Bioactive Dietary VDR Ligands Regulate Genes Encoding Biomarkers of Skin Repair That Are Associated with Risk for Psoriasis (pp. 174). Basel/MDPI: Nutrients.

Chamcheu, J. C., Syed, D. N., Whitfield, G. K. (2018). Nutraceuticals and the Skin: Roles in Health and Disease. Basel/MDPI: NUTRIENTS.

Chamcheu, J. C., Siddiqui, I., Adhami, V., Esnault, S., Bharali, D., Babatunde, A., Adame, S., Massey, R., Wood, G., Longley, B. J., Mousa, S., Mukhtar, H. (2018). Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis (pp. 4189-4206). Int J Nanomedicine ..

Rady, I., Bloch, M. B., Chamcheu, R. N., Banang-Mbeumi, S., Anwar, M. R., Mohamed, H., Babatunde, A., Kuiate, J., Noubissi, F., El Sayed, K., Whitfield, G. K., Chamcheu, J. C. (2018). Anticancer Properties of Graviola ( Annona muricata): A Comprehensive Mechanistic Review. Oxid Med Cell Longev ..

Chamcheu, J. C., Roy, T., Uddin, M. B., Banang-Mbeumi, S., Chamcheu, R. N., WALKER, A. L., HUANG, Y., Huang, S. (2019). Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy (pp. 803). Basel/MDPI: Cells..

Chamcheu, J. C., Esnault, S., Adhami, V., Noll, A., Banang-Mbeumi, S., Roy, T., Singh, S., Huang, S., Kousoulas, K., Mukhtar, H. (2019). Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models (pp. p1089). Basel/MDPI: Cells.

Li, H., DaSilva, N., Liu, W., Xu, J., Dombi, G., Chamcheu, J. C., Seeram, N., Ma, H. (2020). Thymocid ®, a Standardized Black Cumin ( Nigella sativa) Seed Extract, Modulates Collagen Cross-Linking, Collagenase and Elastase Activities, and Melanogenesis in Murine B16F10 Melanoma Cells (pp. 2146). Nutrients.

Roy, K., Uddin, M., Roy, S. C., Hill, R. A., Chamcheu, J. C., Lu, H., Liu, Y. (2020). Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylation. (pp. 653-667). FASEB Bioadv..

Wongjarupong, N., Oli, S., Sanou, M., Djigma, F., Chamcheu, J. C., Simpore, J., Roberts, L., Nagalo, B. (2021). Distribution and Incidence of Blood-Borne Infection among Blood Donors from Regional Transfusion Centers in Burkina Faso: A Comprehensive Study. (pp. 1577–1581). Am J Trop Med Hyg..

Aryal, D., Roy, T., Chamcheu, J. C., Jackson, K. (2020). Chronic Metabolic Acidosis Elicits Hypertension via Upregulation of Intrarenal Angiotensin II and Induction of Oxidative Stress. Monroe: Antioxidants ..

Roy, T., Boateng, S. T., Banang-Mbeumi, S., Singh, P. K., Basnet, P., WALKER, R. L., WALKER, A. L., Hill, R. A., Kousoulas, K. G., Chamcheu, J. C. (2021). Synthesis, Inverse Docking-Assisted Identification and in vitro Biological Characterization of Flavonol-based Analogs of Fisetin as c-Kit, CDK2 and mTOR Inhibitors against Melanoma and Non-melanoma Skin Cancers. (pp. 19). Bioorganic Chemistry.

Roy, T., Boateng, S. T., Banang-Mbeumi, S. B., Singh, P. K., Basnet, P., Chamcheu, R. N., WALKER, K. L., WALKER, A. L., Hill, R. A., Chamcheu, J. C. (2021). Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation. (pp. 19). Data-In-Brief.

CHAMCHEU, J. C., RADY, I., N. Chamcheu, R., SIDDIQUE, A., BLOCH, B., Banang-Mbeumi, S., BABATUNDE, S., ADAME, S., MASSEY, R., MOUSA, S., WOOD, G. (2018). Graviola (Annona muricata) Exerts Anti-Proliferative, Anti-Clonogenic and Pro-Apoptotic Effects in Human Non-Melanoma Skin Cancer UW-BCC1 and A431 Cells In Vitro: Involvement of Hedgehog Signaling. Basel/MDPI: IJMS.

Karrys, A., Islam, R., N. Chamcheu, R., Sabir, M. S., Mallick, S., Chamcheu, J. C., JURUTKA, P. W., HAUSSLER, M. R., KERR WHITFIELD, G. (2018). Bioactive Dietary VDR Ligands Regulate Genes Encoding Biomarkers Implicated in Skin Repair that Are Associated with Risk for Psoriasis. Basel/MDPI: NUTRIENTS.

Chamcheu, J. C., Roy, T., Uddin, M., Banang-Mbeumi, S. C., N. Chamcheu, R., WALKER, A., LIU, Y., HUANG, S. (2019). Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents (pp. 803). Basel/MDPI: Cells.

CHAMCHEU, J. C., Pavez-Loriè, E., Akgul, B., Bannbers, E., Virtanen, M., Gammon, L., Moustakas, A., Navsaria, H., Vahlquist, A., Törmä, H. (2009). Characterization of immortalized human epidermolysis bullosa simplex (KRT5) cell lines: Trimethylamine N-oxide protects the keratin cytoskeleton against disruptive stress condition. (pp. 198-206.). J Dermatol Sci..

CHAMCHEU, J. C., Syed, D. N., Whitfield, G. (2018). Nutraceuticals and the Skin: Roles in Health and Disease. MDPI.

CHAMCHEU, J., Adhami, V. M., MUKHTAR, H. (2015). Cutaneous Cell- and Gene-Based Therapies for Inherited and Acquired Skin in the book entitled Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Disorders. CRC Press, Taylor and Francis Group.

Siddiqui, I. A., Tarapore, R. S., CHAMCHEU, J. C., Mukhtar, H. (2011). Bioactive Food Components for Melanoma: An Overview (pp. 214). InTech Publishers.

Research Grants

Chamcheu, J. C. (Principal), WALKER, A. (Supporting), EL Sayed, K. (Supporting), Jois, S. (Supporting), Liu, Y. (Supporting), Jackson, K. (Supporting), "Role of mTOR/Rho and related pathways and their targeting in psoriasis development and control" (Not Funded), Sponsored By NIH-NIAMS, External to The University of Louisiana at Monroe, $3,010,465. (July 1 2022 - June 30 2027).

Chamcheu, J. C. (Principal), EL Sayed, K. A. (Supporting), Jois, S. (Supporting), Briski, K. P. (Supporting), WALKER, A. L. (Supporting), Bhattacharjee, J. (Supporting), "Role of mTOR/Rho and related pathways and their targeting in psoriasis development and control" (Pending Funding Decision), Sponsored By NIH, External to The University of Louisiana at Monroe, $1,682,782.00. (December 1 2021 - November 30 2026).

Chamcheu, J. C. (Principal), JACKSON, K. (Supporting), WALKER, A. (Supporting), "A Co-Targeting mTOR and IL-17A as a Novel Lead for Psoriasis Control" (Not Funded), Sponsored By NIH-NIAMS, External to The University of Louisiana at Monroe, $426,450. (March 1 2023 - February 28 2026).

Chamcheu, J. C. (Principal), LIU, Y. (Supporting), Degiussep, S. (Supporting), NAGALO, B. M. (Supporting), "Role of pharmacologic small molecules in enhancing VSV-based oncolytic viral therapy in melanoma" (Pending Funding Decision), Sponsored By NIH, External to The University of Louisiana at Monroe, $405,932. (July 07 2023 - June 30 2025).

Chamcheu, J. C. (Principal), EL Sayed, K. A. (Supporting), WALKER, A. L. (Supporting), Jois, S. (Supporting), Briski, K. P. (Supporting), Bhattacharjee, J. (Supporting), "Co-targeting mTOR/epidermal Rac1 and IL-17A as a novel therapeutic lead for psoriasis control" (Not Funded), Sponsored By NIH, External to The University of Louisiana at Monroe, $415,210.01. (December 1 2021 - November 30 2024).

Chamcheu, J. C. (Principal), EL Sayed, K. A. (Supporting), Liu, Y. (Supporting), Jackson, K. (Supporting), Jois, S. (Supporting), "Role and Modulation of mTOR/Rac1 Pathway in Skin Inflammation and Psoriasis" (Funded), Sponsored By Louisiana Board of Regent Support Fund RCS, External to The University of Louisiana at Monroe, $123,225. (June 1 2021 - June 30 2024).

Chamcheu, J. C. (Principal), JOIS, S. (Supporting), EL Sayed, K. (Supporting), Liu, Y. (Supporting), Jackson, K. (Supporting), "Role and modulation of mTOR/Rac1 pathway in skin inflammation and psoriasis" (Funded), Sponsored By Board of Regent Support Fund RCS, External to The University of Louisiana at Monroe, $123,575. (June 1 2021 - May 30 2024).

Chamcheu, J. C., "Development of fisetin as a novel inhibitor co-targeting the PI3K/Akt/mTOR and IL-17A for treating psoriasis" (Funded), Sponsored By LOUISIANA STATE UNIVERSITY BATON ROUGE, External to The University of Louisiana at Monroe, $431,000. (May 1 2021 - April 30 2024).

Chamcheu, J. C. (Principal), EL Sayed, K. (Supporting), Liu, Y. (Supporting), Briski, K. P. (Supporting), Jois, S. D. (Supporting), Kousoulas, K. G. (Supporting), Batchajaree, J. (Supporting), "Development of fisetin as a novel inhibitor co-targeting PI3K/AKT/mTOR/Rac1 and IL-17A for Treating Psoriasis" (Funded), Sponsored By LBRN-NIH, External to The University of Louisiana at Monroe, $415,600. (May 1 2021 - April 30 2024).

Chamcheu, J. C. (Principal), WALKER, A. L. (Supporting), Patial, S. (Co-Principal), "Myeloid mTOR signaling and the efficacy of fisetin in psoriasis" (Not Funded), Sponsored By NIH, External to The University of Louisiana at Monroe, $400,026.00. (December 1 2020 - November 30 2023).

CHAMCHEU, J. (Principal), EL Sayed, K. A. (Supporting), Liu, Y. (Supporting), Briski, K. P. (Supporting), Jois, S. (Supporting), Bhattacharjee, J. (Supporting), "Co-targeting mTOR/epidermal Rac1 and IL-17A with fisetin as a novel therapeutic lead to control psoriasis" (Not Funded), Sponsored By NIH/NIGMS, External to The University of Louisiana at Monroe, $412,307.86. (July 1 2020 - July 30 2023).

Chamcheu, J. C. (Co-Principal), DeGiussep, S. (Co-Principal), "Development of a three-dimensional human skin equivalent cell culture model to investigate poxvirus infection" (Funded), Sponsored By VCOM, External to The University of Louisiana at Monroe, $40,000. (July 07 2022 - June 30 2023).

BREWER, K. (Principal), Chamcheu, J. C. (Co-Principal), "Developing a fisetin Nanoparticle Assembly as a Treatment for Psoriasis" (Not Funded), Sponsored By NIH/SBIR, External to The University of Louisiana at Monroe, $239,776. (March 07 2022 - November 6 2022).

Bock, C. (Principal), Chamcheu, J. C. (Co-Principal), "Evaluation of the regulatory effects of natural and novel synthetic derivatives of fisetin on the Hedgehog targets GLI1, PTCH1 and Notch in nonmelanoma skin cancer cell lines" (Not Funded), Sponsored By AAPS-AFPE Gateway to Research Awards, External to The University of Louisiana at Monroe, $5,000. (June 1 2021 - August 31 2022).

CHAMCHEU, J. C. (Principal), El Sayed, K. A. (Supporting), Jois, S. D. (Supporting), Liu, Y. (Supporting), "FISETIN: A NOVEL AGENT FOR THE TREATMENT OF PSORIASIS" (Not Funded), Sponsored By Louisiana Biomedical Research Network, External to The University of Louisiana at Monroe, $406054. (June 2 2019 - May 30 2022).

CHAMCHEU, J. C. (Principal), El Sayed, K. A. (Supporting), Jois, S. D. (Supporting), Liu, Y. (Supporting), Jackson, K. (Supporting), "Developing fisetin, a novel natural product co-targeting the PI3K/AKT/mTOR and MAPK for the management of psoriasis" (Not Funded), Sponsored By BoR SUPPORT FUND Research Competitiveness Subprogram, External to The University of Louisiana at Monroe, $161914. (June 1 2019 - May 30 2022).

Chamcheu, J. C. (Principal), El Sayed, K. (Supporting), "Discovery and hit-to-lead promotion of novel anti-skin cancers graviola (Annona muricata) extract ingredient" (Not Funded), Sponsored By University of Louisiana at Monroe College of Pharmacy, The University of Louisiana at Monroe, $4,500. (April 1 2021 - March 30 2022).

Chamcheu, J. C. (Principal), "Bioguided fractionation and identification of graviola extract ingredients and their in vitro anti-skin cancer evaluation" (Funded), Sponsored By LBRN, External to The University of Louisiana at Monroe, $19,000. (June 1 2021 - August 13 2021).

CHAMCHEU, J. (Co-Principal), Mukhtar, H. (Principal), "Targeting PI3K/Akt/mTOR for the management of psoriasis" (Funded), Sponsored By NIH/NIAMS, External to The University of Louisiana at Monroe, $1,250,000. (September 1 2015 - July 31 2021).

WALKER, A. (Principal), CHAMCHEU, J. C. (Supporting), Matthaiolampakis, G., "Formulation of Pluronic Lecithin Organogel (PLO) as a transdermal delivery vehicle of the flavonol fisetin" (Not Funded), Sponsored By NIH/LSU INBRE (LBRN), External to The University of Louisiana at Monroe, $66,244.52. (May 1 2020 - April 30 2021).

WALKER, A. (Principal), CHAMCHEU, J. (Supporting), Matthaiolampakis, G. (Supporting), "Exploration of a potent anti-proliferative and anti-inflammatory pleuronic lecithin organogel (PLO) flavonol-derivative as an efficient transdermal delivery vehicle" (Not Funded), Sponsored By ULM College of Pharmacy, The University of Louisiana at Monroe, $4,499. (March 1 2020 - February 28 2021).

JACKSON, K. E. (Principal), WALKER, A. (Co-Principal), CHAMCHEU, J. C. (Co-Principal), "Improved Access to Health Care in Northeast Louisiana" (Funded), Sponsored By Blue Cross Blue Shield of Louisiana, External to The University of Louisiana at Monroe, $2,000. (January 19 2019 - December 30 2020).

JACKSON, K. (Principal), WALKER, A. (Supporting), CHAMCHEU, J. C. (Supporting), ""Promotion of Enhanced Health Care"" (Funded), Sponsored By Living Well Foundation, External to The University of Louisiana at Monroe, $15,000. (January 19 2019 - December 30 2020).

Chamcheu, J. C. (Principal), "Role of mTOR and its targeting by fisetin for treating psoriasis" (Funded), Sponsored By NIH/LSU INBRE (LBRN), External to The University of Louisiana at Monroe, $84600. (August 1 2019 - August 18 2020).

Chamcheu, J. C. (Principal), "Characterization of Antiproliferative Activity of Ursnic Acid Derivatives in Melanoma and Non-Melanoma Skin Cancer Cells" (Funded), Sponsored By ULM COP FRS Grant, External to The University of Louisiana at Monroe, $500. (April 1 2020 - August 11 2020).

WALKER, A. L. (Principal), EVANS, J. (Supporting), CHAMCHEU, J. C. (Supporting), BARBO, A. (Supporting), "Reducing Costs by Using In-House Prepared Simulated Medications Instead of Commercial Products in a Pharmacy School Practice Laboratory" (Funded), Sponsored By ULM Academic Innovation Center, The University of Louisiana at Monroe, $4,499.00. (January 2 2019 - January 2 2020).

CHAMCHEU, J. (Principal), Walker, A. (Supporting), EL Sayed, K. A. (Supporting), Jois, S. D. (Supporting), "Co-targeting PI3K/Akt/mTOR and MAPK by the natural product fisetin to control psoriasis" (Not Funded), Sponsored By PHRMA Foundation, External to The University of Louisiana at Monroe, $98,000. (January 30 2019 - December 30 2019).

CHAMCHEU, J. C. (Principal), El Sayed, K. A. (Supporting), Jois, S. D. (Supporting), Kousoulas, K. (Supporting), Liu, Y. (Supporting), "Validation of the role of PI3K/Akt/mTOR signaling in psoriasis and its targeting" (Funded), Sponsored By LBRN, External to The University of Louisiana at Monroe, $61193. (May 01 2018 - April 30 2019).

CHAMCHEU, J. (Principal), "Targeting psoriasis-related cytokines-induced keratinocyte responses by fisetin for enhanced psoriasis control." (Funded), Sponsored By University of Louisiana Monroe college of pharmacy, The University of Louisiana at Monroe, $4500. (April 30 2018 - March 30 2019).

Meyer, S. (Principal), El Sayed, K. (Co-Principal), Jackson, k. (Co-Principal), Chamcheu, J. C. (Co-Principal), "Ultra-high-performance liquid chromatography capability to enhance research and training among ULM toxicology, chemistry and pharmacology" (Not Funded), Sponsored By Board of Regent Support Fund RCS LA BoR Department Enhancement, External to The University of Louisiana at Monroe, $91,645. (2019).

CHAMCHEU, J. C. (Principal), "Synthesis and preclinical studies of novel anti-cancer fusarochromanone analog" (Funded), Sponsored By Louisiana Biomedical Research Network, External to The University of Louisiana at Monroe, $7500. (May 21 2018 - July 27 2018).

CHAMCHEU, J. (Principal), "Development and validation of a novel full-thickness three-dimensional Human Skin Equivalent Model of Psoriasis" (Funded), Sponsored By University of Wisconsin-Madison-Skin Disease Research Center, External to The University of Louisiana at Monroe, $45,000. (September 01 2016 - March 30 2018).

Awards & Honors

March 2023 Best Graduate Student Poster Award.

June 2022 Excellence in Team Teaching Award: Therapeutics VII..

May 2022 2022 Future Leaders Retreat for URM PhD Student.

May 2022 2022 Future Leaders Retreat for PhD Student.

May 2022 Graduate Student Travel Award.

May 2022 URM Graduate Student Travel Award.

May 2021 Excellence in Team Teaching Award: Therapeutics VII..

February 2021 LBRN Best Graduate Research Podium Presentation Award (1st place)..

May 2020 Excellence in Team Teaching Award: Therapeutics VII..

March 2020 Louisiana Academy of Sciences Undergraduate Best Poster Award (1st place)..

March 2019 Louisiana Academy of Sciences Undergraduate Best Poster Award .

January 2019 LBRN Best Undergraduate Poster Award (3rd Place) .

May 2016 SID Podium Presentation Award.

May 2016 Junior Scientists Travel Award.

May 2016 Society for Investigative Dermatology Fellow Travel Award .

April 2016 American Skin Association Carson Research Scholar Award in Psoriasis .

May 2012 PhD-Resident Retreat Award.

May 2011 Pachyonychia Congenita Travel Award .

November 2005 Rene Tourain Foundation travel Award.

May 2005 Pre-doctoral Travel Award.

2004 Skin Biology and Keratin Diseases Scholarship.

June 2003 Mouaffo Gabriel Medical Foundation Scholarship.

March Best Undegraduate Student Poster Award.

Courses Taught

PHAR 5016STERILE PRODUCTS, 2 course(s)

PHRD 4008PHARMACEUTICS I, 4 course(s)

PHRD 4012PATHOPHYSIOLOGY I, 4 course(s)

PHRD 4027PRINCIPLES OF DRUG ACTION II, 6 course(s)

PHRD 4035PATHOPHYSIOLOGY II, 5 course(s)

PHRD 5037EYES, EARS, THROAT & DERM MOD, 2 course(s)

PHRD 5039THERAPEUTICS VII, 4 course(s)

PHRD 5064PROBLEMS, 1 course(s)

Jean Christopher Chamcheu, PhD Assistant Professor, Pharmacy